만성 B형 간염 시장 : 약물 클래스별, 성별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)

The global chronic hepatitis B market was valued at $4,589.8 million in 2021 and is projected to reach $6,213.15 million by 2031, registering a CAGR of 3.0% from 2022 to 2031.  Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). Hepatitis B can cause chronic infection and increases the risk of death from cirrhosis and liver cancer.

The increase in rate of hepatitis B and rise in awareness about hepatitis B drive the growth of the market. For instance, according to a report of World Health Organization (WHO) published in June 2022, globally, an estimated 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year. Thus, increase in prevalence of hepatitis B globally boosts the growth of the market.

In addition, factors such as increase in blood donation and rise in blood transfusion rate foster the growth of the market. The blood transfusion is a leading cause of hepatitis B virus transmission. For instance, as per the report of World Health Organization (WHO) published in May 2022, about 118.54 million blood donations are made worldwide. About 40% of these are collected in high-income countries. The World Health Organization (WHO) recommends that all blood donations should be screened for infections prior to use. Screening for HIV, hepatitis B, hepatitis c, and syphilis should be mandatory.

Moreover, increase in R&D activities for development of novel chronic hepatitis B treatment, rise in the U.S. food & drug administration (FDA) approvals and novel product launch in the market by key players boost the market growth. For instance, in June 2022, glaxosmithkline (GSK), a science-led global healthcare company, announced the interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks' treatment in people with chronic hepatitis B (CHB). Furthermore, advancements in hepatitis B treatment and rise in diagnosis rate further contribute toward the market growth. However, high cost of chronic hepatitis B drugs is projected to hinder the growth of the market.

The chronic hepatitis B market is segmented on the basis of drug class, gender, distribution channel, and region. By drug class, the market is fragmented into antivirals, and immune modulators. By gender, the market is classified into male, and female. The male segment is further divided into adult and geriatric. The female segment is further divided into adult and geriatric. By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online providers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The major companies profiled in the report include Biocon Inc, Cipla Limited, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Novartis AG, Reliance Life Sciences, Sun Pharmaceutical Industries Limited, Teva pharmaceuticals, Viatris Inc and Zydus Cadila.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chronic hepatitis b (chb) market analysis from 2021 to 2031 to identify the prevailing chronic hepatitis b (chb) market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the chronic hepatitis b (chb) market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global chronic hepatitis b (chb) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Class

• Antivirals
• Immune Modulators

By Gender

• Male
  • Age Group
  • Adult
  • Geriartic
• Female
  • Age Group
  • Adult
  • Geriartic

By Distribution Channel

• Hospital Pharmacies
• Drug Stores and Retail Pharmacies
• Online Providers

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest Of Europe
• Asia-Pacific
  • Japan
  • China
  • Australia
  • India
  • South Korea
  • Rest Of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest Of LAMEA
• Key Market Players
  • GlaxoSmithKline (GSK)
  • Gilead Sciences, Inc.
  • Merck & Co. Inc.
  • Bristol Myers Squibb Co.
  • Teva Pharmaceutical Industries Limited
  • zydus cadila
  • Novartis AG
  • F. Hoffman La Roche, Ltd.
  • Viatris Inc. (Mylan NV)
  • Cipla Ltd

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

• 1.1.Report description
• 1.2.Key market segments
• 1.3.Key benefits to the stakeholders
• 1.4.Research Methodology
  • 1.4.1.Secondary research
  • 1.4.2.Primary research
  • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

• 2.1.Key findings of the study
• 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

• 3.1.Market definition and scope
• 3.2.Key findings
  • 3.2.1.Top investment pockets
• 3.3.Porter's five forces analysis
• 3.4.Top player positioning
• 3.5.Market dynamics
  • 3.5.1.Drivers
  • 3.5.2.Restraints
  • 3.5.3.Opportunities
• 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: CHRONIC HEPATITIS B (CHB) MARKET, BY DRUG CLASS

• 4.1 Overview
  • 4.1.1 Market size and forecast
• 4.2 Antivirals
  • 4.2.1 Key market trends, growth factors and opportunities
  • 4.2.2 Market size and forecast, by region
  • 4.2.3 Market analysis by country
• 4.3 Immune Modulators
  • 4.3.1 Key market trends, growth factors and opportunities
  • 4.3.2 Market size and forecast, by region
  • 4.3.3 Market analysis by country

CHAPTER 5: CHRONIC HEPATITIS B (CHB) MARKET, BY GENDER

• 5.1 Overview
  • 5.1.1 Market size and forecast
• 5.2 Male
  • 5.2.1 Key market trends, growth factors and opportunities
  • 5.2.2 Market size and forecast, by region
  • 5.2.3 Market analysis by country
  • 5.2.4 Male Chronic Hepatitis B (CHB) Market by Age Group
    • 5.2.4.1 Adult Market size and forecast, by region
    • 5.2.4.2 Geriartic Market size and forecast, by region
• 5.3 Female
  • 5.3.1 Key market trends, growth factors and opportunities
  • 5.3.2 Market size and forecast, by region
  • 5.3.3 Market analysis by country
  • 5.3.4 Female Chronic Hepatitis B (CHB) Market by Age Group
    • 5.3.4.1 Adult Market size and forecast, by region
    • 5.3.4.2 Geriartic Market size and forecast, by region

CHAPTER 6: CHRONIC HEPATITIS B (CHB) MARKET, BY DISTRIBUTION CHANNEL

• 6.1 Overview
  • 6.1.1 Market size and forecast
• 6.2 Hospital Pharmacies
  • 6.2.1 Key market trends, growth factors and opportunities
  • 6.2.2 Market size and forecast, by region
  • 6.2.3 Market analysis by country
• 6.3 Drug Stores and Retail Pharmacies
  • 6.3.1 Key market trends, growth factors and opportunities
  • 6.3.2 Market size and forecast, by region
  • 6.3.3 Market analysis by country
• 6.4 Online Providers
  • 6.4.1 Key market trends, growth factors and opportunities
  • 6.4.2 Market size and forecast, by region
  • 6.4.3 Market analysis by country

CHAPTER 7: CHRONIC HEPATITIS B (CHB) MARKET, BY REGION

• 7.1 Overview
  • 7.1.1 Market size and forecast
• 7.2 North America
  • 7.2.1 Key trends and opportunities
  • 7.2.2 North America Market size and forecast, by Drug Class
  • 7.2.3 North America Market size and forecast, by Gender
    • 7.2.3.1 North America Male Chronic Hepatitis B (CHB) Market by Age Group
    • 7.2.3.2 North America Female Chronic Hepatitis B (CHB) Market by Age Group
  • 7.2.4 North America Market size and forecast, by Distribution Channel
  • 7.2.5 North America Market size and forecast, by country
    • 7.2.5.1 U.S.
    • 7.2.5.1.1 Market size and forecast, by Drug Class
    • 7.2.5.1.2 Market size and forecast, by Gender
    • 7.2.5.1.3 Market size and forecast, by Distribution Channel
    • 7.2.5.2 Canada
    • 7.2.5.2.1 Market size and forecast, by Drug Class
    • 7.2.5.2.2 Market size and forecast, by Gender
    • 7.2.5.2.3 Market size and forecast, by Distribution Channel
    • 7.2.5.3 Mexico
    • 7.2.5.3.1 Market size and forecast, by Drug Class
    • 7.2.5.3.2 Market size and forecast, by Gender
    • 7.2.5.3.3 Market size and forecast, by Distribution Channel
• 7.3 Europe
  • 7.3.1 Key trends and opportunities
  • 7.3.2 Europe Market size and forecast, by Drug Class
  • 7.3.3 Europe Market size and forecast, by Gender
    • 7.3.3.1 Europe Male Chronic Hepatitis B (CHB) Market by Age Group
    • 7.3.3.2 Europe Female Chronic Hepatitis B (CHB) Market by Age Group
  • 7.3.4 Europe Market size and forecast, by Distribution Channel
  • 7.3.5 Europe Market size and forecast, by country
    • 7.3.5.1 Germany
    • 7.3.5.1.1 Market size and forecast, by Drug Class
    • 7.3.5.1.2 Market size and forecast, by Gender
    • 7.3.5.1.3 Market size and forecast, by Distribution Channel
    • 7.3.5.2 France
    • 7.3.5.2.1 Market size and forecast, by Drug Class
    • 7.3.5.2.2 Market size and forecast, by Gender
    • 7.3.5.2.3 Market size and forecast, by Distribution Channel
    • 7.3.5.3 UK
    • 7.3.5.3.1 Market size and forecast, by Drug Class
    • 7.3.5.3.2 Market size and forecast, by Gender
    • 7.3.5.3.3 Market size and forecast, by Distribution Channel
    • 7.3.5.4 Italy
    • 7.3.5.4.1 Market size and forecast, by Drug Class
    • 7.3.5.4.2 Market size and forecast, by Gender
    • 7.3.5.4.3 Market size and forecast, by Distribution Channel
    • 7.3.5.5 Spain
    • 7.3.5.5.1 Market size and forecast, by Drug Class
    • 7.3.5.5.2 Market size and forecast, by Gender
    • 7.3.5.5.3 Market size and forecast, by Distribution Channel
    • 7.3.5.6 Rest of Europe
    • 7.3.5.6.1 Market size and forecast, by Drug Class
    • 7.3.5.6.2 Market size and forecast, by Gender
    • 7.3.5.6.3 Market size and forecast, by Distribution Channel
• 7.4 Asia-Pacific
  • 7.4.1 Key trends and opportunities
  • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class
  • 7.4.3 Asia-Pacific Market size and forecast, by Gender
    • 7.4.3.1 Asia-Pacific Male Chronic Hepatitis B (CHB) Market by Age Group
    • 7.4.3.2 Asia-Pacific Female Chronic Hepatitis B (CHB) Market by Age Group
  • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
  • 7.4.5 Asia-Pacific Market size and forecast, by country
    • 7.4.5.1 Japan
    • 7.4.5.1.1 Market size and forecast, by Drug Class
    • 7.4.5.1.2 Market size and forecast, by Gender
    • 7.4.5.1.3 Market size and forecast, by Distribution Channel
    • 7.4.5.2 China
    • 7.4.5.2.1 Market size and forecast, by Drug Class
    • 7.4.5.2.2 Market size and forecast, by Gender
    • 7.4.5.2.3 Market size and forecast, by Distribution Channel
    • 7.4.5.3 Australia
    • 7.4.5.3.1 Market size and forecast, by Drug Class
    • 7.4.5.3.2 Market size and forecast, by Gender
    • 7.4.5.3.3 Market size and forecast, by Distribution Channel
    • 7.4.5.4 India
    • 7.4.5.4.1 Market size and forecast, by Drug Class
    • 7.4.5.4.2 Market size and forecast, by Gender
    • 7.4.5.4.3 Market size and forecast, by Distribution Channel
    • 7.4.5.5 South Korea
    • 7.4.5.5.1 Market size and forecast, by Drug Class
    • 7.4.5.5.2 Market size and forecast, by Gender
    • 7.4.5.5.3 Market size and forecast, by Distribution Channel
    • 7.4.5.6 Rest of Asia-Pacific
    • 7.4.5.6.1 Market size and forecast, by Drug Class
    • 7.4.5.6.2 Market size and forecast, by Gender
    • 7.4.5.6.3 Market size and forecast, by Distribution Channel
• 7.5 LAMEA
  • 7.5.1 Key trends and opportunities
  • 7.5.2 LAMEA Market size and forecast, by Drug Class
  • 7.5.3 LAMEA Market size and forecast, by Gender
    • 7.5.3.1 LAMEA Male Chronic Hepatitis B (CHB) Market by Age Group
    • 7.5.3.2 LAMEA Female Chronic Hepatitis B (CHB) Market by Age Group
  • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
  • 7.5.5 LAMEA Market size and forecast, by country
    • 7.5.5.1 Brazil
    • 7.5.5.1.1 Market size and forecast, by Drug Class
    • 7.5.5.1.2 Market size and forecast, by Gender
    • 7.5.5.1.3 Market size and forecast, by Distribution Channel
    • 7.5.5.2 Saudi Arabia
    • 7.5.5.2.1 Market size and forecast, by Drug Class
    • 7.5.5.2.2 Market size and forecast, by Gender
    • 7.5.5.2.3 Market size and forecast, by Distribution Channel
    • 7.5.5.3 South Africa
    • 7.5.5.3.1 Market size and forecast, by Drug Class
    • 7.5.5.3.2 Market size and forecast, by Gender
    • 7.5.5.3.3 Market size and forecast, by Distribution Channel
    • 7.5.5.4 Rest of LAMEA
    • 7.5.5.4.1 Market size and forecast, by Drug Class
    • 7.5.5.4.2 Market size and forecast, by Gender
    • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

• 9.1 GlaxoSmithKline (GSK)
  • 9.1.1 Company overview
  • 9.1.2 Company snapshot
  • 9.1.3 Operating business segments
  • 9.1.4 Product portfolio
  • 9.1.5 Business performance
  • 9.1.6 Key strategic moves and developments
• 9.2 Gilead Sciences, Inc.
  • 9.2.1 Company overview
  • 9.2.2 Company snapshot
  • 9.2.3 Operating business segments
  • 9.2.4 Product portfolio
  • 9.2.5 Business performance
  • 9.2.6 Key strategic moves and developments
• 9.3 Merck & Co. Inc.
  • 9.3.1 Company overview
  • 9.3.2 Company snapshot
  • 9.3.3 Operating business segments
  • 9.3.4 Product portfolio
  • 9.3.5 Business performance
  • 9.3.6 Key strategic moves and developments
• 9.4 Bristol Myers Squibb Co.
  • 9.4.1 Company overview
  • 9.4.2 Company snapshot
  • 9.4.3 Operating business segments
  • 9.4.4 Product portfolio
  • 9.4.5 Business performance
  • 9.4.6 Key strategic moves and developments
• 9.5 Teva Pharmaceutical Industries Limited
  • 9.5.1 Company overview
  • 9.5.2 Company snapshot
  • 9.5.3 Operating business segments
  • 9.5.4 Product portfolio
  • 9.5.5 Business performance
  • 9.5.6 Key strategic moves and developments
• 9.6 zydus cadila
  • 9.6.1 Company overview
  • 9.6.2 Company snapshot
  • 9.6.3 Operating business segments
  • 9.6.4 Product portfolio
  • 9.6.5 Business performance
  • 9.6.6 Key strategic moves and developments
• 9.7 Novartis AG
  • 9.7.1 Company overview
  • 9.7.2 Company snapshot
  • 9.7.3 Operating business segments
  • 9.7.4 Product portfolio
  • 9.7.5 Business performance
  • 9.7.6 Key strategic moves and developments
• 9.8 F. Hoffman La Roche, Ltd.
  • 9.8.1 Company overview
  • 9.8.2 Company snapshot
  • 9.8.3 Operating business segments
  • 9.8.4 Product portfolio
  • 9.8.5 Business performance
  • 9.8.6 Key strategic moves and developments
• 9.9 Viatris Inc. (Mylan NV)
  • 9.9.1 Company overview
  • 9.9.2 Company snapshot
  • 9.9.3 Operating business segments
  • 9.9.4 Product portfolio
  • 9.9.5 Business performance
  • 9.9.6 Key strategic moves and developments
• 9.10 Cipla Ltd
  • 9.10.1 Company overview
  • 9.10.2 Company snapshot
  • 9.10.3 Operating business segments
  • 9.10.4 Product portfolio
  • 9.10.5 Business performance
  • 9.10.6 Key strategic moves and developments